Equity Profile

RPRX

Royalty Pharma plc

Health CarePharmaceuticals$26.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2017Pre-Market9:00 AM EDT

Company Snapshot

Royalty Pharma plc (RPRX) is a healthcare company that specializes in acquiring and managing revenue-generating pharmaceutical royalties. With a market cap of $26 billion, it plays a significant role in the pharmaceutical industry by providing funding to biotech and pharmaceutical companies, which can help bring new treatments to market.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

$1.18

Revenue

Revenue figures provide insight into the company's sales performance and growth potential.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter (Q3-2017), Royalty Pharma reported an EPS of -$0.04, which did not meet analyst expectations. The revenue figures were also not disclosed, leaving investors uncertain about the company's performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Royalty Pharma's upcoming earnings, expecting an EPS of $1.18 and revenue of $874 million. The company has struggled in previous quarters, which adds a layer of uncertainty to these expectations.

Bull Case

If Royalty Pharma meets or exceeds the EPS and revenue estimates, it could signal a turnaround in financial performance, boosting investor confidence and stock price.

Bear Case

Conversely, if the company fails to meet these estimates, it may raise concerns about its ability to generate consistent revenue, leading to a potential decline in stock value.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$874M

Revenue figures provide insight into the company's sales performance and growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Royalty Pharma achieve an EPS of at least $1.18?

This figure is crucial for assessing the company's profitability and could significantly impact investor sentiment.

What revenue figures will Royalty Pharma report, and how do they compare to the $874 million consensus?

Revenue performance is key to understanding the company's growth trajectory and ability to generate cash flow.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly optimistic about Royalty Pharma's ability to meet EPS expectations given its recent performance history.

Supporting Evidence

The company has consistently reported negative EPS in recent quarters, raising doubts about its turnaround potential.

Options pricing suggests a significant move, indicating uncertainty that may not be fully reflected in analyst estimates.

Key Risk

If the EPS comes in below $1.17, it could undermine the bullish sentiment and lead to a reassessment of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these metrics to determine whether Royalty Pharma can turn around its recent performance.

Bull Confirmed If

Achieving an EPS of $1.18 or higher would confirm a positive outlook and potentially attract more investors.

Bear Confirmed If

An EPS below $1.17 would raise serious concerns about the company's profitability and future growth.

Pre-Earnings Positioning

Options Market

Implied Move

±12.3%

The options market is pricing in a significant move of approximately 12.3%, indicating that traders expect volatility around the earnings report.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests the stock could rise by an average of 2.89% on the first day, confirming a positive trend.

In-Line / Cautious

If the results are in line with expectations, the stock may see a muted reaction as investors weigh management's commentary.

Miss

A miss could lead to a decline, with historical data indicating an average drop of 2.09% within five days.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or acquisitions that could impact revenue.
2Management's outlook on future revenue growth and market conditions.
3Details on cost management strategies and their impact on profitability.
4Insights into the performance of key products and their contribution to revenue.
5Any changes in guidance or expectations for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

$1.18

Revenue

Revenue figures provide insight into the company's sales performance and growth potential.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Royalty Pharma meets or exceeds the EPS and revenue estimates, it could signal a turnaround in financial performance, boosting investor confidence and stock price.

Bear Case

Conversely, if the company fails to meet these estimates, it may raise concerns about its ability to generate consistent revenue, leading to a potential decline in stock value.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$874M

Revenue figures provide insight into the company's sales performance and growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Royalty Pharma achieve an EPS of at least $1.18?

This figure is crucial for assessing the company's profitability and could significantly impact investor sentiment.

What revenue figures will Royalty Pharma report, and how do they compare to the $874 million consensus?

Revenue performance is key to understanding the company's growth trajectory and ability to generate cash flow.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly optimistic about Royalty Pharma's ability to meet EPS expectations given its recent performance history.

Supporting Evidence

The company has consistently reported negative EPS in recent quarters, raising doubts about its turnaround potential.

Options pricing suggests a significant move, indicating uncertainty that may not be fully reflected in analyst estimates.

Key Risk

If the EPS comes in below $1.17, it could undermine the bullish sentiment and lead to a reassessment of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these metrics to determine whether Royalty Pharma can turn around its recent performance.

Bull Confirmed If

Achieving an EPS of $1.18 or higher would confirm a positive outlook and potentially attract more investors.

Bear Confirmed If

An EPS below $1.17 would raise serious concerns about the company's profitability and future growth.

Pre-Earnings Positioning

Options Market

Implied Move

±12.3%

The options market is pricing in a significant move of approximately 12.3%, indicating that traders expect volatility around the earnings report.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests the stock could rise by an average of 2.89% on the first day, confirming a positive trend.

In-Line / Cautious

If the results are in line with expectations, the stock may see a muted reaction as investors weigh management's commentary.

Miss

A miss could lead to a decline, with historical data indicating an average drop of 2.09% within five days.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or acquisitions that could impact revenue.
2Management's outlook on future revenue growth and market conditions.
3Details on cost management strategies and their impact on profitability.
4Insights into the performance of key products and their contribution to revenue.
5Any changes in guidance or expectations for the upcoming quarters.